NASDAQ:FLKS - Flex Pharma Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$3.89 0.00 (0.00 %)
(As of 05/23/2018 04:00 PM ET)
Previous Close$3.89
Today's Range$3.84 - $3.99
52-Week Range$2.68 - $8.98
Volume35,448 shs
Average Volume78,724 shs
Market Capitalization$68.81 million
P/E Ratio-1.95
Dividend YieldN/A
Beta2.97

About Flex Pharma (NASDAQ:FLKS)

Flex Pharma logoFlex Pharma, Inc., a biotechnology company, develops and commercializes products for the treatment of muscle cramps, spasms, and spasticity associated with neurological conditions and exercise in the United States. It operates in two segments, Consumer Operations and Drug Development. The company's lead drug candidate is FLX-787, a single molecule, chemically synthesized, and dual transient receptor potential V1/A1 ion channel activator, which is in exploratory Phase 2 clinical trial in Australia for the treatment of patients with multiple sclerosis; and two Phase 2 clinical trials in the United States for the treatment of patients with motor neuron disease in amyotrophic lateral sclerosis. It also offers HOTSHOT, a consumer beverage to prevent and treat exercise associated muscle cramps. The company markets and sells its HOTSHOT product online through its e-commerce Website, as well as through specialty retailers. Flex Pharma, Inc. was founded in 2014 and is headquartered in Boston, Massachusetts.

Receive FLKS News and Ratings via Email

Sign-up to receive the latest news and ratings for FLKS and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:FLKS
CUSIPN/A
Phone617-874-1821

Debt

Debt-to-Equity RatioN/A
Current Ratio6.22
Quick Ratio6.12

Price-To-Earnings

Trailing P/E Ratio-1.95
Forward P/E Ratio-2.22
P/E GrowthN/A

Sales & Book Value

Annual Sales$1.27 million
Price / Sales55.16
Cash FlowN/A
Price / CashN/A
Book Value$1.21 per share
Price / Book3.21

Profitability

EPS (Most Recent Fiscal Year)($1.99)
Net Income$-34,430,000.00
Net Margins-2,842.07%
Return on Equity-104.48%
Return on Assets-90.59%

Miscellaneous

Employees22
Outstanding Shares18,010,000

Flex Pharma (NASDAQ:FLKS) Frequently Asked Questions

What is Flex Pharma's stock symbol?

Flex Pharma trades on the NASDAQ under the ticker symbol "FLKS."

How were Flex Pharma's earnings last quarter?

Flex Pharma Inc (NASDAQ:FLKS) announced its quarterly earnings data on Wednesday, May, 2nd. The biotechnology company reported ($0.46) EPS for the quarter, beating the consensus estimate of ($0.50) by $0.04. The biotechnology company earned $0.18 million during the quarter, compared to analysts' expectations of $0.30 million. Flex Pharma had a negative net margin of 2,842.07% and a negative return on equity of 104.48%. View Flex Pharma's Earnings History.

What price target have analysts set for FLKS?

4 equities research analysts have issued 1 year price targets for Flex Pharma's stock. Their forecasts range from $6.00 to $40.00. On average, they expect Flex Pharma's share price to reach $17.50 in the next year. View Analyst Ratings for Flex Pharma.

What are Wall Street analysts saying about Flex Pharma stock?

Here are some recent quotes from research analysts about Flex Pharma stock:
  • 1. According to Zacks Investment Research, "Flex Pharma, Inc. is a biotechnology company. The Company is involved in developing treatments for nocturnal leg cramps and spasms associated with severe neuromuscular conditions. Flex Pharma, Inc. is headquartered in Boston, Massachusetts. " (5/7/2018)
  • 2. Cantor Fitzgerald analysts commented, "Exploratory Phase II study of FLX-787 in MS showed statistically significant reduction of 27.3% (p=0.001) in frequency of cramps and a 1.4-day increase in the number of cramp-free days (p=0.0457)." (3/27/2018)

Who are some of Flex Pharma's key competitors?

Who are Flex Pharma's key executives?

Flex Pharma's management team includes the folowing people:
  • Dr. Roderick MacKinnon, Co-Founder, Co-Chair of Scientific Advisory Board & Director (Age 62)
  • Dr. Thomas C. Wessel, Chief Medical Officer (Age 62)
  • Dr. William K. McVicar, Pres, CEO & Director (Age 60)
  • Mr. Robert Hadfield, Advisor (Age 40)
  • Dr. Bruce Bean, Co-Founder, Co-Chair of Scientific Advisory Board & Board Observer

When did Flex Pharma IPO?

(FLKS) raised $60 million in an IPO on Thursday, January 29th 2015. The company issued 4,600,000 shares at a price of $12.00-$14.00 per share. Jefferies and Piper Jaffray served as the underwriters for the IPO and JMP Securities, Cantor Fitzgerald and Roth Capital Partners were co-managers.

Has Flex Pharma been receiving favorable news coverage?

News coverage about FLKS stock has trended somewhat positive on Wednesday, Accern Sentiment reports. The research firm scores the sentiment of media coverage by analyzing more than twenty million blog and news sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Flex Pharma earned a media sentiment score of 0.20 on Accern's scale. They also assigned news articles about the biotechnology company an impact score of 45.90 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock's share price in the next several days.

Who are Flex Pharma's major shareholders?

Flex Pharma's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include C WorldWide Group Holding A S (1.19%), Millennium Management LLC (0.33%) and JPMorgan Chase & Co. (0.21%). Company insiders that own Flex Pharma stock include Christoph H Westphal and John P Mccabe. View Institutional Ownership Trends for Flex Pharma.

Which institutional investors are selling Flex Pharma stock?

FLKS stock was sold by a variety of institutional investors in the last quarter, including C WorldWide Group Holding A S. View Insider Buying and Selling for Flex Pharma.

Which institutional investors are buying Flex Pharma stock?

FLKS stock was acquired by a variety of institutional investors in the last quarter, including JPMorgan Chase & Co. and Millennium Management LLC. Company insiders that have bought Flex Pharma stock in the last two years include Christoph H Westphal and John P Mccabe. View Insider Buying and Selling for Flex Pharma.

How do I buy shares of Flex Pharma?

Shares of FLKS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Flex Pharma's stock price today?

One share of FLKS stock can currently be purchased for approximately $3.89.

How big of a company is Flex Pharma?

Flex Pharma has a market capitalization of $68.81 million and generates $1.27 million in revenue each year. The biotechnology company earns $-34,430,000.00 in net income (profit) each year or ($1.99) on an earnings per share basis. Flex Pharma employs 22 workers across the globe.

How can I contact Flex Pharma?

Flex Pharma's mailing address is 800 Boylston Street 24thFloor, Boston MA, 02199. The biotechnology company can be reached via phone at 617-874-1821 or via email at [email protected]


MarketBeat Community Rating for Flex Pharma (FLKS)

Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  250 (Vote Outperform)
Underperform Votes:  173 (Vote Underperform)
Total Votes:  423
MarketBeat's community ratings are surveys of what our community members think about Flex Pharma and other stocks. Vote "Outperform" if you believe FLKS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe FLKS will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Flex Pharma (NASDAQ:FLKS) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
4 Wall Street analysts have issued ratings and price targets for Flex Pharma in the last 12 months. Their average twelve-month price target is $17.50, suggesting that the stock has a possible upside of 349.87%. The high price target for FLKS is $40.00 and the low price target for FLKS is $6.00. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.752.752.802.75
Ratings Breakdown: 0 Sell Rating(s)
1 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $17.50$9.50$10.80$11.00
Price Target Upside: 349.87% upside34.75% upside168.66% upside214.29% upside

Flex Pharma (NASDAQ:FLKS) Consensus Price Target History

Price Target History for Flex Pharma (NASDAQ:FLKS)

Flex Pharma (NASDAQ:FLKS) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/3/2018HC WainwrightReiterated RatingBuy$40.00HighView Rating Details
3/27/2018Cantor FitzgeraldSet Price TargetHold$6.00HighView Rating Details
1/25/2018Ladenburg ThalmannInitiated CoverageBuy ➝ Buy$12.00HighView Rating Details
1/3/2018Roth CapitalReiterated RatingBuy ➝ Buy$12.00LowView Rating Details
5/4/2017Jefferies GroupLower Price TargetBuy$9.00 ➝ $8.00HighView Rating Details
3/8/2017Piper Jaffray CompaniesSet Price TargetBuy$12.00LowView Rating Details
11/3/2016JMP SecuritiesReiterated RatingBuyN/AView Rating Details
(Data available from 5/23/2016 forward)

Earnings

Flex Pharma (NASDAQ:FLKS) Earnings History and Estimates Chart

Earnings by Quarter for Flex Pharma (NASDAQ:FLKS)

Flex Pharma (NASDAQ:FLKS) Earnings Estimates

2018 EPS Consensus Estimate: ($1.49)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20181($0.45)($0.45)($0.45)
Q2 20181($0.39)($0.39)($0.39)
Q3 20181($0.40)($0.40)($0.40)
Q4 20181($0.25)($0.25)($0.25)

Flex Pharma (NASDAQ FLKS) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/2/2018Q1 2018($0.50)($0.46)$0.30 million$0.18 millionViewListenView Earnings Details
3/7/2018Q4 2017($0.56)($0.46)$0.36 million$0.28 millionViewListenView Earnings Details
11/6/2017Q3 2017($0.60)($0.54)$0.47 million$0.41 millionViewN/AView Earnings Details
8/2/2017Q2 2017($0.63)($0.51)$0.46 million$0.34 millionViewListenView Earnings Details
5/3/2017Q1 2017($0.62)($0.49)$0.38 million$0.24 millionViewListenView Earnings Details
3/8/2017Q4 2016($0.84)($0.48)$0.09 million$0.30 millionViewListenView Earnings Details
11/2/2016Q316($0.72)($0.65)$0.15 million$0.60 millionViewListenView Earnings Details
8/3/2016Q216($0.67)($0.71)$0.01 million$0.11 millionViewListenView Earnings Details
5/4/2016Q1($0.56)($0.61)ViewListenView Earnings Details
3/8/2016Q415($0.56)($0.51)ViewListenView Earnings Details
11/4/2015Q315($0.44)($0.53)ViewListenView Earnings Details
8/5/2015Q215($0.37)($0.47)ViewListenView Earnings Details
5/6/2015Q1($0.32)($0.59)ViewListenView Earnings Details
3/17/2015Q4($0.12)($1.82)ViewListenView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Flex Pharma (NASDAQ:FLKS) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Flex Pharma (NASDAQ FLKS) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 7.62%
Institutional Ownership Percentage: 27.80%
Insider Trading History for Flex Pharma (NASDAQ:FLKS)
Institutional Ownership by Quarter for Flex Pharma (NASDAQ:FLKS)

Flex Pharma (NASDAQ FLKS) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
11/8/2016Christoph H WestphalInsiderBuy7,000$7.31$51,170.003,941,118View SEC Filing  
11/7/2016Christoph H WestphalInsiderBuy8,870$5.70$50,559.003,934,118View SEC Filing  
11/7/2016John P MccabeVPBuy1,650$6.01$9,916.501,650View SEC Filing  
6/23/2016Christoph H WestphalCEOBuy2,700$11.28$30,456.003,925,248View SEC Filing  
6/22/2016Christoph H WestphalCEOBuy5,700$11.05$62,985.003,925,248View SEC Filing  
6/21/2016Christoph H WestphalCEOBuy2,800$11.07$30,996.003,925,248View SEC Filing  
6/20/2016Christoph H WestphalCEOBuy6,000$11.18$67,080.003,925,248View SEC Filing  
6/16/2016Christoph H WestphalCEOBuy5,800$11.17$64,786.003,925,248View SEC Filing  
6/14/2016Christoph H WestphalCEOBuy5,900$11.54$68,086.003,925,248View SEC Filing  
6/10/2016Christoph H WestphalCEOBuy6,000$11.94$71,640.003,925,248View SEC Filing  
6/8/2016Christoph H WestphalCEOBuy5,900$12.25$72,275.003,925,248View SEC Filing  
6/6/2016Christoph H WestphalCEOBuy6,000$12.56$75,360.003,925,248View SEC Filing  
6/2/2016Christoph H WestphalCEOBuy10,000$12.99$129,900.003,925,248View SEC Filing  
5/31/2016Christoph H WestphalCEOBuy22,300$12.68$282,764.003,925,248View SEC Filing  
5/26/2016Christoph H WestphalCEOBuy28,600$12.84$367,224.003,925,248View SEC Filing  
5/24/2016Christoph H WestphalCEOBuy30,334$12.42$376,748.283,925,248View SEC Filing  
5/20/2016Christoph H WestphalCEOBuy7,914$11.06$87,528.843,925,248View SEC Filing  
5/18/2016Christoph H WestphalCEOBuy33,400$11.10$370,740.003,925,248View SEC Filing  
5/16/2016Christoph H WestphalCEOBuy15,469$10.25$158,557.253,925,248View SEC Filing  
5/12/2016Christoph H WestphalCEOBuy30,217$10.12$305,796.043,925,248View SEC Filing  
5/10/2016Christoph H WestphalCEOBuy30,109$9.94$299,283.463,925,248View SEC Filing  
3/24/2016Christoph H WestphalCEOBuy49,563$11.06$548,166.783,925,248View SEC Filing  
3/22/2016Christoph H WestphalCEOBuy23,951$11.78$282,142.78View SEC Filing  
3/21/2016Christoph H WestphalCEOBuy48,058$11.74$564,200.923,925,248View SEC Filing  
3/18/2016Christoph H WestphalCEOBuy37,574$11.00$413,314.003,925,248View SEC Filing  
3/16/2016Christoph H WestphalCEOBuy38,379$10.23$392,617.173,925,248View SEC Filing  
3/15/2016Michelle StacyDirectorBuy2,585$9.63$24,893.552,585View SEC Filing  
3/14/2016Thomas WesselInsiderBuy20,000$7.94$158,800.0049,064View SEC Filing  
3/11/2016Christoph H WestphalCEOBuy89,680$7.00$627,760.003,925,248View SEC Filing  
3/11/2016Roderick MackinnonDirectorBuy10,000$7.03$70,300.00431,277View SEC Filing  
12/14/2015Christoph H WestphalCEOBuy927$12.01$11,133.273,925,248View SEC Filing  
12/7/2015Christoph H WestphalCEOBuy907$12.02$10,902.143,924,321View SEC Filing  
11/19/2015Marc D KozinDirectorBuy4,500$11.38$51,210.004,500View SEC Filing  
11/16/2015Christoph H WestphalCEOBuy1,001$10.78$10,790.783,921,556View SEC Filing  
11/9/2015Christoph H WestphalCEOBuy1,000$11.03$11,030.003,920,555View SEC Filing  
10/26/2015Christoph H WestphalCEOBuy1,043$10.55$11,003.653,918,588View SEC Filing  
10/19/2015Christoph H WestphalCEOBuy1,018$10.61$10,800.983,917,545View SEC Filing  
9/28/2015Christoph H WestphalCEOBuy924$11.18$10,330.323,914,735View SEC Filing  
3/30/2015Christoph H WestphalCEOBuy272$20.52$5,581.44View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Flex Pharma (NASDAQ FLKS) News Headlines

Source:
DateHeadline
MEI Pharma (MEIP) and Flex Pharma (FLKS) Head to Head ReviewMEI Pharma (MEIP) and Flex Pharma (FLKS) Head to Head Review
www.americanbankingnews.com - May 21 at 9:22 PM
Flex Pharma (FLKS) Expected to Announce Quarterly Sales of $290,000.00Flex Pharma (FLKS) Expected to Announce Quarterly Sales of $290,000.00
www.americanbankingnews.com - May 20 at 4:21 AM
Zacks: Brokerages Anticipate Flex Pharma (FLKS) Will Post Earnings of -$0.46 Per ShareZacks: Brokerages Anticipate Flex Pharma (FLKS) Will Post Earnings of -$0.46 Per Share
www.americanbankingnews.com - May 18 at 12:44 PM
Flex Pharma (FLKS) Rating Lowered to Hold at Zacks Investment ResearchFlex Pharma (FLKS) Rating Lowered to Hold at Zacks Investment Research
www.americanbankingnews.com - May 8 at 12:16 AM
Flex Pharma to Post Q2 2018 Earnings of ($0.39) Per Share, Jefferies Group Forecasts (FLKS)Flex Pharma to Post Q2 2018 Earnings of ($0.39) Per Share, Jefferies Group Forecasts (FLKS)
www.americanbankingnews.com - May 7 at 2:13 AM
Flex Pharma (FLKS) Receives Consensus Rating of "Buy" from AnalystsFlex Pharma (FLKS) Receives Consensus Rating of "Buy" from Analysts
www.americanbankingnews.com - May 5 at 1:33 AM
ValuEngine Upgrades Flex Pharma (FLKS) to "Sell"ValuEngine Upgrades Flex Pharma (FLKS) to "Sell"
www.americanbankingnews.com - May 4 at 12:13 AM
Flex Pharma (FLKS) Issues  Earnings Results, Beats Estimates By $0.04 EPSFlex Pharma (FLKS) Issues Earnings Results, Beats Estimates By $0.04 EPS
www.americanbankingnews.com - May 3 at 7:29 PM
Flex Pharma (FLKS) Given "Buy" Rating at HC WainwrightFlex Pharma (FLKS) Given "Buy" Rating at HC Wainwright
www.americanbankingnews.com - May 3 at 4:31 PM
Edited Transcript of FLKS earnings conference call or presentation 2-May-18 1:00pm GMTEdited Transcript of FLKS earnings conference call or presentation 2-May-18 1:00pm GMT
finance.yahoo.com - May 3 at 8:41 AM
Flex Pharmas (FLKS) CEO Bill McVicar on Q1 2018 Results - Earnings Call TranscriptFlex Pharma's (FLKS) CEO Bill McVicar on Q1 2018 Results - Earnings Call Transcript
seekingalpha.com - May 2 at 5:11 PM
Flex Pharma beats by $0.03, misses on revenueFlex Pharma beats by $0.03, misses on revenue
seekingalpha.com - May 2 at 8:47 AM
Flex Pharma: 1Q Earnings SnapshotFlex Pharma: 1Q Earnings Snapshot
finance.yahoo.com - May 2 at 8:47 AM
Zacks: Brokerages Anticipate Flex Pharma (FLKS) Will Post Quarterly Sales of $300,000.00Zacks: Brokerages Anticipate Flex Pharma (FLKS) Will Post Quarterly Sales of $300,000.00
www.americanbankingnews.com - May 2 at 2:02 AM
Does Flex Pharma Inc’s (NASDAQ:FLKS) Latest Financial Perfomance Look Strong?Does Flex Pharma Inc’s (NASDAQ:FLKS) Latest Financial Perfomance Look Strong?
finance.yahoo.com - May 1 at 8:51 AM
Zacks: Analysts Anticipate Flex Pharma (FLKS) to Post -$0.50 EPSZacks: Analysts Anticipate Flex Pharma (FLKS) to Post -$0.50 EPS
www.americanbankingnews.com - April 30 at 7:12 PM
Flex Pharma to Report First Quarter 2018 Financial Results on May 2, 2018Flex Pharma to Report First Quarter 2018 Financial Results on May 2, 2018
finance.yahoo.com - April 25 at 5:10 PM
Flex Pharma (FLKS) Set to Announce Earnings on TuesdayFlex Pharma (FLKS) Set to Announce Earnings on Tuesday
www.americanbankingnews.com - April 24 at 8:24 AM
Flex Pharma (FLKS) Raised to Buy at Zacks Investment ResearchFlex Pharma (FLKS) Raised to Buy at Zacks Investment Research
www.americanbankingnews.com - April 18 at 11:10 AM
$300,000.00 in Sales Expected for Flex Pharma Inc (FLKS) This Quarter$300,000.00 in Sales Expected for Flex Pharma Inc (FLKS) This Quarter
www.americanbankingnews.com - April 15 at 2:14 AM
 Brokerages Anticipate Flex Pharma Inc (FLKS) Will Announce Earnings of -$0.50 Per Share Brokerages Anticipate Flex Pharma Inc (FLKS) Will Announce Earnings of -$0.50 Per Share
www.americanbankingnews.com - April 13 at 9:16 PM
Flex Pharma Inc (FLKS) Receives Consensus Rating of "Hold" from AnalystsFlex Pharma Inc (FLKS) Receives Consensus Rating of "Hold" from Analysts
www.americanbankingnews.com - April 10 at 1:41 AM
Flex Pharma (FLKS) Rating Increased to Buy at Zacks Investment ResearchFlex Pharma (FLKS) Rating Increased to Buy at Zacks Investment Research
www.americanbankingnews.com - April 8 at 12:40 AM
Flex Pharma (FLKS) Stock Rating Lowered by Zacks Investment ResearchFlex Pharma (FLKS) Stock Rating Lowered by Zacks Investment Research
www.americanbankingnews.com - April 7 at 3:53 PM
Flex Pharma (FLKS) Downgraded to "Sell" at Zacks Investment ResearchFlex Pharma (FLKS) Downgraded to "Sell" at Zacks Investment Research
www.americanbankingnews.com - March 31 at 4:56 PM
Flex Pharma (FLKS) Rating Lowered to Sell at Zacks Investment ResearchFlex Pharma (FLKS) Rating Lowered to Sell at Zacks Investment Research
www.americanbankingnews.com - March 31 at 12:10 PM
 Brokerages Expect Flex Pharma Inc (FLKS) Will Announce Quarterly Sales of $300,000.00 Brokerages Expect Flex Pharma Inc (FLKS) Will Announce Quarterly Sales of $300,000.00
www.americanbankingnews.com - March 29 at 2:28 AM
Flex Pharma (FLKS) Stock Rating Lowered by ValuEngineFlex Pharma (FLKS) Stock Rating Lowered by ValuEngine
www.americanbankingnews.com - March 28 at 10:22 PM
Flex Pharma (FLKS) Announces Positive Topline Data from Exploratory Phase 2 Trial of FLX-787 in Multiple SclerosisFlex Pharma (FLKS) Announces Positive Topline Data from Exploratory Phase 2 Trial of FLX-787 in Multiple Sclerosis
www.streetinsider.com - March 28 at 8:59 AM
Zacks: Analysts Expect Flex Pharma Inc (FLKS) to Post -$0.50 Earnings Per ShareZacks: Analysts Expect Flex Pharma Inc (FLKS) to Post -$0.50 Earnings Per Share
www.americanbankingnews.com - March 27 at 11:14 PM
Flex Pharma (FLKS) Stock Rating Reaffirmed by Cantor FitzgeraldFlex Pharma (FLKS) Stock Rating Reaffirmed by Cantor Fitzgerald
www.americanbankingnews.com - March 27 at 9:53 AM
Flex Pharmas FLX-787 shows treatment effect in MS patients with cramps/spasms in exploratory study; shares up 6%Flex Pharma's FLX-787 shows treatment effect in MS patients with cramps/spasms in exploratory study; shares up 6%
seekingalpha.com - March 26 at 4:53 PM
Today’s Research Reports on Stocks to Watch: Flex Pharma, Inc. and Alexion PharmaceuticalsToday’s Research Reports on Stocks to Watch: Flex Pharma, Inc. and Alexion Pharmaceuticals
finance.yahoo.com - March 16 at 8:53 AM
Flex Pharma Inc (FLKS) Receives Average Recommendation of "Hold" from BrokeragesFlex Pharma Inc (FLKS) Receives Average Recommendation of "Hold" from Brokerages
www.americanbankingnews.com - March 16 at 1:36 AM
Flex Pharma (FLKS) Upgraded to Sell at ValuEngineFlex Pharma (FLKS) Upgraded to Sell at ValuEngine
www.americanbankingnews.com - March 16 at 12:48 AM
Research Analysts Offer Predictions for Flex Pharma Incs Q1 2018 Earnings (FLKS)Research Analysts Offer Predictions for Flex Pharma Inc's Q1 2018 Earnings (FLKS)
www.americanbankingnews.com - March 12 at 2:30 AM
Flex Pharma (FLKS) Posts  Earnings Results, Beats Expectations By $0.10 EPSFlex Pharma (FLKS) Posts Earnings Results, Beats Expectations By $0.10 EPS
www.americanbankingnews.com - March 8 at 10:29 AM
Cantor Fitzgerald Analysts Give Flex Pharma (FLKS) a $6.00 Price TargetCantor Fitzgerald Analysts Give Flex Pharma (FLKS) a $6.00 Price Target
www.americanbankingnews.com - March 7 at 4:15 PM
Flex Pharma Reports Year End 2017 Financial ResultsFlex Pharma Reports Year End 2017 Financial Results
www.bizjournals.com - March 7 at 8:51 AM
Should You Buy Flex Pharma Inc (NASDAQ:FLKS) Now?Should You Buy Flex Pharma Inc (NASDAQ:FLKS) Now?
finance.yahoo.com - March 7 at 8:51 AM
Flex Pharma to Report Fourth Quarter and Full Year 2017 Results on March 7, 2018Flex Pharma to Report Fourth Quarter and Full Year 2017 Results on March 7, 2018
finance.yahoo.com - February 28 at 5:38 PM
$360,000.00 in Sales Expected for Flex Pharma Inc (FLKS) This Quarter$360,000.00 in Sales Expected for Flex Pharma Inc (FLKS) This Quarter
www.americanbankingnews.com - February 23 at 2:02 AM
Zacks: Analysts Expect Flex Pharma Inc (FLKS) to Post -$0.85 EPSZacks: Analysts Expect Flex Pharma Inc (FLKS) to Post -$0.85 EPS
www.americanbankingnews.com - February 21 at 11:14 PM
Flex Pharma Inc (FLKS) Receives Consensus Rating of "Buy" from BrokeragesFlex Pharma Inc (FLKS) Receives Consensus Rating of "Buy" from Brokerages
www.americanbankingnews.com - February 19 at 1:32 AM
Zacks Investment Research Upgrades Flex Pharma (FLKS) to HoldZacks Investment Research Upgrades Flex Pharma (FLKS) to Hold
www.americanbankingnews.com - February 15 at 11:22 PM
Flex Pharma Inc to Post FY2018 Earnings of ($1.68) Per Share, Jefferies Group Forecasts (FLKS)Flex Pharma Inc to Post FY2018 Earnings of ($1.68) Per Share, Jefferies Group Forecasts (FLKS)
www.americanbankingnews.com - February 15 at 11:40 AM
Jefferies Group Comments on Flex Pharma Incs FY2022 Earnings (FLKS)Jefferies Group Comments on Flex Pharma Inc's FY2022 Earnings (FLKS)
www.americanbankingnews.com - February 14 at 4:12 PM
New Study Shows HOTSHOT™ Provides Relief From Muscle Soreness For Athletes Of All TypesNew Study Shows HOTSHOT™ Provides Relief From Muscle Soreness For Athletes Of All Types
finance.yahoo.com - February 8 at 8:29 AM
Flex Pharma Presenting at BIO CEO on February 13, 2018Flex Pharma Presenting at BIO CEO on February 13, 2018
finance.yahoo.com - February 6 at 4:00 PM
Summit Therapeutics (SMMT) vs. Flex Pharma (FLKS) Head-To-Head ContrastSummit Therapeutics (SMMT) vs. Flex Pharma (FLKS) Head-To-Head Contrast
www.americanbankingnews.com - February 6 at 1:19 PM

SEC Filings

Flex Pharma (NASDAQ:FLKS) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Flex Pharma (NASDAQ:FLKS) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Flex Pharma (NASDAQ FLKS) Stock Chart for Wednesday, May, 23, 2018

Loading chart…

This page was last updated on 5/23/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.